Table 3. Canada’s strength of collaboration with other top producers of stem cell research, 2006–2010.
2006 | 2007 | 2008 | 2009 | 2010 | Average | |
US | 0.089 | 0.096 | 0.093 | 0.105 | 0.104 | 0.097 |
UK | 0.039 | 0.028 | 0.049 | 0.056 | 0.055 | 0.045 |
Germany | 0.027 | 0.041 | 0.052 | 0.054 | 0.045 | 0.044 |
Australia | 0.044 | 0.024 | 0.033 | 0.041 | 0.044 | 0.037 |
France | 0.042 | 0.037 | 0.029 | 0.042 | 0.035 | 0.037 |
South Korea | 0.026 | 0.026 | 0.036 | 0.040 | 0.024 | 0.030 |
Japan | 0.019 | 0.030 | 0.029 | 0.027 | 0.034 | 0.028 |
Italy | 0.020 | 0.018 | 0.025 | 0.028 | 0.025 | 0.023 |
Brazil | 0.020 | 0.028 | 0.003 | 0.034 | 0.019 | 0.021 |
Spain | 0.011 | 0.023 | 0.012 | 0.023 | 0.029 | 0.020 |
China | 0.018 | 0.018 | 0.016 | 0.021 | 0.021 | 0.019 |
India | 0.000 | 0.004 | 0.010 | 0.003 | 0.007 | 0.005 |
Shown is the strength of Canada’s collaboration (indicated by Salton’s measure – the larger the number, the stronger the mutual strength of the collaboration between the two countries) with the other top 10 global producers of stem cell research, as well as for comparison – Australia, and emerging economies India and Brazil.